Animalcare is a leading supplier of generic veterinary medicines and animal identification products to companion animal veterinary markets.

It develops and sells goods and services to veterinary professionals principally for use in companion animals; operating through UK wholesalers and distribution and development partners in key markets in Western Europe.

Its principal product lines are licensed veterinary medicines and companion animal identification products and services.

(AIM:ANCR)

http://www.animalcaregroup.co.uk/

20 shares for the future

Trading update & Notice of Interim Results
RNS
RNS Number : 5900T
Animalcare Group PLC
09 January 2017
 
 
Animalcare Group plc
(the 'Group' or the 'Company')
 
Trading update & Notice of Interim Results
 
Animalcare Group plc (AIM: ANCR), a leading supplier of veterinary medicines,  provides a trading update for the first six months of the current financial year ahead of publishing its interim results on 15th February 2017. Following a very strong first half-year for the Group, the Board is pleased to announce that it expects that trading for the year ending 30th June 2017 will be ahead of current market expectations.
 
Trading Update
 
Trading during the period has been ahead of the Board's expectations in both sales and profit terms, which saw revenue growth of 12.0% versus the same period last year to £7.97m (2015: £7.11m).
 
The Licensed Veterinary Medicines group continued to grow strongly in the first half with revenues increasing 17.2% to £5.37m (2015: £4.58m), driven by growth in the UK of 14.6% and outside the UK of 37.7%. Sales from new products launched in the period contributed around £0.20m, or 4%, of the overall 17.2% growth. Gross margins have improved versus the prior year through a combination of favourable sales mix and cost of goods initiatives.
 
Sales from the Animal Welfare Products group improved by 13.4% to £1.51m (2016: £1.34m) driven by continued strong growth of our infusion accessories range.
 
The Companion Animal Identification group revenues decreased by 9.2% to £1.09m (2016: £1.20m). Following the implementation of compulsory microchipping of dogs in the United Kingdom in April 2016, we expected and have observed a reduction in microchip volumes, which we expect to last into the medium-term. Database services however have continued to grow.
 
 The Group's cash position remains strong with period end cash balances at approximately £7.0m (30th June 2016: £7.1m, 31st December 2015: £6.1m). As expected, we have made a significant net investment in working capital to support growth.
 
Summary and Outlook
 
Four products were launched in the first half; three as part of a range of ear cleaners and treatments, all on distribution, and one new product from our in-house development pipeline, Acecare (a companion animal sedative).
 
It is expected that there will be two further product launches in H2, both on distribution from EU partners and both for use with companion animals.
 
As we highlighted in our FY16 results in October, despite the uncertainty of Brexit, the Board took the decision to accelerate investment in new products on the strength of continued positive trading momentum and the Group's strong financial position. We are pleased to report good progress in our product development pipeline, in particular with regard to the identification of novel formulations which, as previously stated, are strategic focus for the Group. We expect expenditure on our pipeline to increase for the current financial year to around £2.0m (FY16: £1.6m).
 
Following a very strong first half-year for the Group, the Board is pleased to announce that for the year ending 30th June 2017 it expects trading will be ahead of current market expectations and revenues to be in line with the first half.

Half year report

Highlights
·    Strong revenue growth from our Licensed Veterinary Medicines group, up 17.2% to £5.37m (2015: £4.58m) driven by strong domestic and export like-for-like growth of 13.0%, and 4.2% contribution from sales of four new products launched in the period.
·    Revenues from the Animal Welfare Products range increased 13.3% to £1.51m (2015: £1.34m).
·    Continued focus on our export business started delivering significant commercial benefit with revenues up 37.7% versus prior period.
·    Momentum in our product development pipeline continues with expenditure in the period of £0.6m and anticipated full year investment increasing to £2.0m (FY16: £1.6m).

15 Feb
Panmure Gordon
385.00
Buy

Animalcare Group PLC (ANCR:LSE) set a new 52-week high during today's trading session when it reached 355.00. Over this period, the share price is up 73.17%.

i thought this was going to be a dog of a share. Obviously I should have vetted it's progress! :o)

Going in to orbit. :-))

Without a paws! ;o)

paw joke. :-))

Yeah, a bit ruff! :o)

Animalcare Group PLC (ANCR:LSE) set a new 52-week high during today's trading session when it reached 460.00. Over this period, the share price is up 96.51%.
52-week range
Today